Home/D&A Pharma/Raphaël Debrégeas

RD

Raphaël Debrégeas

General Counsel and Company Secretary

Therapeutic Areas

Alcohol Use Disorder (AUD)Addiction Narcolepsy Orphan Diseases

D&A Pharma Pipeline

Drug	Indication	Phase
Hopveus® (Sodium Oxybate)	Alcohol Use Disorder (AUD) - maintenance of abstinence	Phase 3/Approval
Sodium Oxybate (one-nightly)	Narcolepsy	Development

Leadership Team at D&A Pharma

Patrice Debrégeas

President and Qualified Person (QP)

Special Advisor to the President

Monique Couderc

Head of Medical & Regulatory Affairs

View full D&A Pharma profile